Table 2.
APOE genotype and neurodegenerative blood biomarkers in superagers and typical older adults.
| Superagers (n=64) | Typical older adults (n=55) | Mean difference (95% CI) | Group comparison test statistic | p value for the mean or distribution difference | False discovery rate p value | |
|---|---|---|---|---|---|---|
| APOE alleles | ||||||
| ɛ2, ɛ3 | 7 (11%) | 10 (18%) | .. | .. | 0·47* | 0·86 |
| ɛ3, ɛ3 | 47 (73%) | 37 (67%) | .. | .. | 0·47* | 0·86 |
| ɛ3, ɛ4 | 10 (16%) | 7 (13%) | .. | .. | 0·47* | 0·86 |
| ɛ4, ɛ4 | 0 | 1 (2%) | .. | .. | 0·47* | 0·86 |
| Blood biomarkers of neurodegeneration | ||||||
| Amyloid-β42 to amyloid-β40 ratio, pg/mL | −2·74 (0·26) | −2·79 (0·24) | 0·05 (−0·04 to 0·14) | −1·09† | 0·28† | 0·86 |
| Total tau, pg/mL | 0·91 (0·41) | 0·91 (0·24) | 0·00 (−0·12 to 0·12) | −0·04† | 0·97† | 0·97 |
| Phosphorylated tau 181, pg/mL | 1·41 (0·96–1·93) | 1·37 (0·95–2·06) | .. | −0·21‡ | 0·84‡ | 0·97 |
| Phosphorylated tau 181 to amyloid-β42 ratio | 0·12 (0·08–0·18) | 0·12 (0·09–0·20) | .. | −0·75‡ | 0·45‡ | 0·86 |
| Glial fibrillary acidic protein, pg/mL | 5·08 (0·64) | 5·16 (0·69) | −0·08 (−0·33 to 0·16) | −0·69† | 0·49† | 0·86 |
| Neurofilament light polypeptide, pg/mL | 2·78 (0·49) | 2·74 (0·69) | 0·03 (−0·25 to 0·19) | 0·31† | 0·76† | 0·97 |
Data are n (%), mean (SD), or median (IQR). Amyloid-β42, amyloid-β40, total tau, and tau phosphorylated at threonine 181 were measured in plasma. Glial fibrillary acidic protein and neurofilament light polypeptide were measured in serum.
*
Fisher's test.
†
t test (for biomarkers that followed a normal distribution after log-transformation).
‡
Mann-Whitney U test (for biomarkers that did not followed a normal distribution after log-transformation, original values and not log-tranformed were used in the test).